Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
Novelty in Biomedicine,
Vol. 12 No. 4 (2024),
28 September 2024
,
Page 170-175
https://doi.org/10.22037/nbm.v12i4.44677
Abstract
Background: Osteoporosis is a significant concern, especially for individuals undergoing renal transplantation, as it disrupts bone health and increases the risk of fractures. Interventions for osteoporosis aim to address bone-related challenges in patients with renal transplantation, yet concerns persist regarding both efficacy and potential adverse events.
Materials and Methods: We searched PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL databases until December 15, 2023, seeking studies that evaluated the efficacy and adverse events of osteoporosis medications in patients with renal transplantation. The Cochrane tool was utilized to assess the quality of the studies. The statistical analysis was performed using Comprehensive Meta-Analysis software, version 3.0.
Results: We enrolled 594 participants from 7 randomized controlled trials. Combining trial results reveals that using anti-osteoporotic agents (Ibandronate, Risedronate, and Pamidronate) reduces the risk of vertebral fractures compared to the placebo. However, the reduction was not statistically significant (OR: 0.49, CI 95%: 0.20-1.22). Additionally, lumbar spine, femoral neck, and total hip BMD showed no significant differences between anti-osteoporotic agents (Denosumab, Zoledronic acid, Ibandronate, Risedronate, and Pamidronate) and placebo. Moreover, there were no significant differences in adverse events between the interventions and placebo.
Conclusion: The study suggests that anti-osteoporotic agents in renal transplantation patients may be associated with a non-significant lower risk of vertebral fractures compared to a placebo. Findings also indicate no significant differences in adverse events between interventions and placebos. Caution is advised in interpreting these results due to the absence of statistically significant differences, emphasizing the need for further research to enhance our understanding of efficacy and safety in renal transplantation.
- Osteoporosis
- Renal transplantation
- Adverse events
- Efficacy
How to Cite
References
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet. 2011;377(9773):1276-87.
Pazianas M, Miller PD. Osteoporosis and chronic kidney disease–mineral and bone disorder (CKD-MBD): back to basics. American Journal of Kidney Diseases. 2021;78(4):582-589.
Shen Y, Huang X, Wu J, et al. The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990-2019. Frontiers in Endocrinology. 2022;13:882241.
Kulak CAM, Borba VZC, Júnior JK, Custódio MR. Osteoporosis after transplantation. Current osteoporosis reports. 2012;10:48-55.
Marcen R, Caballero C, Uriol O, et al. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients. Paper presented at: Transplantation proceedings2007.
Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinology and metabolism clinics of North America. 2007;36(4):937-63.
Abdalbary M, Sobh M, Elnagar S, et al. Management of osteoporosis in patients with chronic kidney disease. Osteoporosis International. 2022;33(11):2259-74.
Evenepoel P, Cunningham J, Ferrari S, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrology Dialysis Transplantation. 2021;36(1):42-59.
Kovvuru K, Kanduri SR, Vaitla P, et al. Risk factors and management of osteoporosis post-transplant. Medicina. 2020;56(6):302.
Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. 2021;73(3):509-29.
LeBoff M, Greenspan S, Insogna K, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis international. 2022;33(10):2049-102.
Kim B, Cho YJ, Lim W. Osteoporosis therapies and their mechanisms of action. Experimental and therapeutic medicine. 2021;22(6):1-14.
Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020. Bone Regulators and Osteoporosis Therapy. 2020:397-422.
van der Burgh AC, de Keyser CE, Zillikens MC, Stricker BH. The effects of osteoporotic and non-osteoporotic medications on fracture risk and bone mineral density. Drugs. 2021:1-28.
Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG. New therapeutic targets for osteoporosis. Maturitas. 2019;120:1-6.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 2009;151(4):264-9.
Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clinical Journal of The American Society of Nephrology: CJASN. 2018;13(6):962.
Gordon PL, Frassetto LA. Management of osteoporosis in CKD stages 3 to 5. American Journal of Kidney Diseases. 2010;55(5):941-56.
Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Internal Medicine. 2017;56(24):3271-6.
Sayed SA, El Wakeel LM, Elseasi AM, Shawki MA. Evaluation of the Efficacy and Tolerability of Alendronate versus Denosumab in Kidney Transplant Patients with Reduced Bone Mineral Density. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023.
Marques IDB, Araújo MJCLN, Graciolli FG, et al. A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. Journal of the American Society of Nephrology: JASN. 2019;30(2):355.
Bonani M, Frey D, Brockmann J, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. American Journal of Transplantation. 2016;16(6):1882-91.
Smerud K, Dolgos S, Olsen I, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. American journal of transplantation. 2012;12(12):3316-25.
Torregrosa J-V, Fuster D, Gentil M-Á, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation. 2010;89(12):1476-81.
Walsh SB, Altmann P, Pattison J, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. American journal of kidney diseases. 2009;53(5):856-65.
Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. Journal of the American Society of Nephrology. 2003;14(10):2669-76.
- Abstract Viewed: 61 times
- pdf Downloaded: 47 times